Federal Supply Schedule 36F79719D0283
Award Date
10/1/19
Last Date to Order
9/30/25
Federal Agency
Veterans Integrated Service Network 12
Awardee
Lundbeck LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Lundbeck LLC, a global pharmaceutical company, to provide specialized drugs and therapies to treat disorders of the central nervous system. The contract has a ceiling value of $31,500,000 and a period of performance from January 31, 2020 to January 30, 2025, with one-year option periods. The specific drugs being procured under this BPA are Sabril (vigabatrin) for...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a multiple award Federal Supply Schedule (FSS) contract to Neurocrine Biosciences, Inc., a biopharmaceutical company, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule. The contract, valued at up to $6,576,000, allows the VA to issue delivery orders for Neurocrine's pharmaceutical products, primarily the drug VALBENAZINE used to treat neurological movement disorders such as tardive dyskinesia. The VA...
The Department of Veterans Affairs (VA) has awarded Acorda Therapeutics, Inc., a biotechnology company specializing in neurological therapies, an IDV Federal Supply Schedule contract (36F79723D0194) valued at over $16.3 million. This multiple-award contract covers the procurement of drugs, pharmaceuticals, and hematology-related products through September 2028. Under this IDV, the VA Veterans Integrated Service Network 12 has issued firm fixed-price delivery orders for Acorda's Levodopa 42mg...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple award Federal Supply Schedule (FSS-61-IB) contract to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, with a ceiling value of $78 million through July 2025. This contract enables the VA to procure pharmaceuticals and drug products, such as TEGSEDI and ORFADIN, to support healthcare services for veterans. Additionally, the VA National Acquisition Center has awarded a single-award Blanket Purchase Agreement (BPA)...
The Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule (FSS) contract to UCB, Inc., a global biopharmaceutical company, for the procurement of pharmaceutical products under the Pharmaceuticals and Drugs FSS-61-IB contract. Under this contract, UCB, Inc. has been awarded multiple Firm Fixed Price delivery orders and Blanket Purchase Agreements (BPAs) to supply the VA with various drugs, including ZilbrysQ, Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra. The delivery...
The Department of Veterans Affairs awarded a multiple-award federal supply schedule contract to Amryt Pharmaceuticals Inc. with a potential value of $225,000. The schedule is for pharmaceuticals and hematology-related products under contract number 65 IB. This enables ordering through September 2028. Additionally, the Department of Veterans Affairs National Acquisition Center awarded a single-award blanket purchase agreement to Amryt Pharmaceuticals with a value of up to $1,000,000. The BPA...
The U.S. Department of Veterans Affairs (VA) has awarded Sandoz Inc., a Novartis subsidiary, an indefinite delivery vehicle (IDV) under the Federal Supply Schedule for Pharmaceuticals and Drugs (FSS-61-IB). The contract, valued at $16.85 billion, allows the VA, Department of Defense, Bureau of Prisons, and Indian Health Services to order a variety of pharmaceutical products from Sandoz's commercial catalog, including antibiotics, chemotherapy drugs, ophthalmic solutions, psychiatric medications,...
The Department of Veterans Affairs (VA) awarded Xeris Pharmaceuticals, Inc., a small disadvantaged business manufacturer, a multiple-award Federal Supply Schedule (FSS) contract under FSS-61-IB for Pharmaceuticals and Drugs. The $4,119,200 contract has a period of performance from July 2020 to July 2025, allowing the VA's Integrated Service Network 12 to procure a range of Xeris' drug therapies, pharmaceuticals, and hematology products to support healthcare operations for veteran patients....
The Department of Veterans Affairs awarded a Federal Supply Schedule contract to Vyera Pharmaceuticals, LLC to procure drugs, pharmaceuticals, and related hematology products. The potential value of this multiple award schedule is $3.5 million with an ordering period through September 2029. Additionally, the National Acquisition Center established a single award Blanket Purchase Agreement with Vyera Pharmaceuticals on behalf of the Veterans Health Administration. Valued at $450,000, this BPA...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple-award Federal Supply Schedule (FSS) contract to Kyowa Kirin, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the procurement of "Drugs, Pharmaceuticals, & Hematology Related Products." The contract has a ceiling value of $17,788,800 and a period of performance through September 29, 2027. In addition to the FSS contract, the VA's National Acquisition Center has awarded a single-award Blanket...